<DOC>
	<DOCNO>NCT02296814</DOCNO>
	<brief_summary>Study verify efficacy tolerability Sinusitis Hevert SL tablet compare placebo adult patient acute , uncomplicated rhinosinusitis ( inflammation nasal paranasal sinus ) .</brief_summary>
	<brief_title>Efficacy Safety Sinusitis Hevert SL Tablets Compared Placebo Adult Patients With Acute , Uncomplicated Rhinosinusitis</brief_title>
	<detailed_description>Acute rhinosinusitis one common diseases worldwide prevalence 6-15 % large impact quality life socioeconomics . The majority infection viral origin , acute bacterial infection occur 0.5-2 % case . Currently available treatment include variety remedy , like analgesic , inhalation water steam dilute drug , nasal douche spray , decongestant mucolytic remedy well antibiotic . Sinusitis Hevert SL register since 2003 treatment inflammation nose throat region sinus ( sinusitis ) contain eleven homeopathic single substance classically use homeopathy condition , evaluate randomize controlled clinical trial . In multicenter , randomize , double-blind , placebo-controlled , parallel group phase IV study efficacy safety Sinusitis Hevert SL tablet compare placebo adult patient acute , uncomplicated rhinosinusitis shall demonstrate .</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<criteria>1 . Signed informed consent 2 . Male female outpatient , age ≥ 18 ≤ 75 year 3 . Diagnosis acute , uncomplicated ( recurrent acute ) rhinosinusitis characterize Major Rhinosinusitis Symptom Score ( MRSSinv ) ≥ 8 ≤ 15 point individual score facial pain/pressure ( bend ) ≥ 1 ( mild ) ≤ 2 ( moderate ) presence symptom ≤ 3 day prior inclusion Out 5 main rhinosinusitis symptom , least 3 must present . Among , presence nasal congestion facial pain / pressure ( bend ) mandatory . 4 . Women childbearing potential : willingness use contraception method Medical history Diseases 1 . Chronic rhinosinusitis ( i.e . form cause persistent chronic rhinosinusitis ) 2 . Polyposis nasi , recent history 3 . Infection dental origin maxilla 4 . Cystic fibrosis , recent history 5 . Anatomical deviation nasal septum significantly impair nasal paranasal ventilation / air flow 6 . Acute symptom know allergic rhinitis 7 . History smoking within last two year prior study enrolment current smoking habit 8 . Patients asthma 9 . Known hypersensitivity study medication excipients ( asteraceae , lactose , allergy bee venom , etc . ) 10 . Underlying disease lead significant immune deficiency 11 . Signs symptoms bacterial sinusitis require antibiotic treatment ( e.g . fever &gt; 38.3°C , orbital complication , severe unilateral frontal headache toothache ) 12 . Patients progressive autoimmune disease , tuberculosis , leukemia leukemialike disease , multiple sclerosis , inflammatory disease connective tissue , rheumatoid arthritis , Lupus erythematodes , HIV infection chronic viral disease 13 . Patients untreated/unstable thyroid gland disorder ( treatment include iodine supplementation ) 14 . Premenopausal woman ( last menstruation ≤ 1 year prior informed consent ) : nursing pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout study . Acceptable method birth control include transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , double barrier method , sexual abstinence vasectomise partner . 15 . Severe disease liver kidney 16 . Severe somatopathic , neurological / psychiatric diseases 17 . Patients malignant growth process cancer treatment within last two year prior study inclusion . 18 . History alcohol drug abuse Medication 1 . Treatment systemic nasal antibiotic nasal systemic corticosteroid within last 4 week prior study inclusion 2 . Treatment alternative medicine preparation ( homeopathic phytotherapeutical drug ) treatment common cold like symptom immunomodulating property ( Echinacea ) , within last 7 day prior study inclusion 3 . Treatment decongestant ( αsympathomimetics day study inclusion within 5 hour prior screen study ) 4 . Chronic use decongestant remedy 5 . Treatment immunosuppressive medication 8 week prior study inclusion study condition 6 . Systemic antiviral treatment aciclovir ; zanamivir , oseltamivir within 30 day prior study inclusion 7 . Patients require antibiotic treatment condition study entry General 1 . Parallel participation clinical study participation another study within less 6 week prior study inclusion , previous participation study 2 . Legal incapacity / circumstance render patient unable understand nature , scope possible impact study 3 . Patients custody juridical official order 4 . Patients difficulty understanding language ( German ) patient information give 5 . Patients employee trial center , CRO , sponsor authorise representative relatives either study site staff , CRO staff ; sponsor staff authorise representative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>